

National Board of Examinations

Question Paper Name :	DNB Pharmacology Paper2
Subject Name :	DNB Pharmacology Paper2
Creation Date :	2022-12-22 19:38:22
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DNB Pharmacology Paper2

Group Number :	1
Group Id :	3271871372
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DNB Pharmacology Paper2

Section Id :	3271871375
Section Number :	1
Section type :	Offline

Mandatory or Optional : Mandatory

Number of Questions to be attempted : 10

Section Marks : 100

Enable Mark as Answered Mark for Review and Clear Response : Yes

Maximum Instruction Time : 0

Sub-Section Number : 1

Sub-Section Id : 3271871379

Question Shuffling Allowed : No

Is Section Default? : null

Question Number : 1 Question Id : 32718712772 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Describe the mechanisms of antimicrobial resistance and strategies to combat it. Discuss the role of community in preventing antimicrobial resistance. [(4+4)+2]

Question Number : 2 Question Id : 32718712773 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Briefly describe the pharmacotherapy of acute congestive heart failure. Discuss the therapeutic status of SGLT2 inhibitors in the management of heart failure. [5+5]

Question Number : 3 Question Id : 32718712774 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Discuss the management of MRSA and VRE infections in intensive care facility. [5+5]

Question Number : 4 Question Id : 32718712775 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Give an account of pharmacotherapy of acute attack and prophylaxis of migraine. Discuss the recent advances in the treatment of migraine. [(3+3)+4]

Question Number : 5 Question Id : 32718712776 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Enumerate newer insulins. Discuss newer insulin delivery systems? Briefly discuss the rationale of all the pharmacotherapeutic agents used in the management of diabetic ketoacidosis. [2+3+5]

Question Number : 6 Question Id : 32718712777 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

What is drug dependence? Outline the pharmacological modalities for the management of opioid and smoking addictions. [2+(4+4)]

Question Number : 7 Question Id : 32718712778 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Describe presynaptic receptors and their therapeutic implications. [5+5]

Question Number : 8 Question Id : 32718712779 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Enumerate the drugs used for the treatment of epilepsy. Discuss the therapeutic status and adverse effects of levetiracetam. Describe the management of status epilepticus. [3+(3+2)+2]

Question Number : 9 Question Id : 32718712780 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Discuss therapeutic guidelines for the management of rheumatic disease. Discuss the therapeutic status of the biological agents in the treatment of rheumatoid arthritis. [5+5]

Question Number : 10 Question Id : 32718712781 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Enumerate hypolipidemic agents. Describe the mechanism of action, indications and adverse effects of PCSK-9 inhibitors. Discuss the role of using combination of hypolipidemic drugs in the management of familial hypercholesterolemia. [2+(2+1+1)+4]